Discovery opens new opportunities for future medicines to treat obesity

The body's brown fat cells play a key role in the development of obesity and diabetes. Researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, have now discovered that we humans have two different kinds of brown fat cells and not one kind as previously thought. This discovery, now published in Nature Medicine, opens up new opportunities for future medicines that exploit the brown fat cells' ability to consume calories.

Unlike white fat cells, which store the body's surplus energy in the form of fat, brown fat cells have the unique property of being able to burn energy and turn it into heat.

The study now published by the researchers at the University of Gothenburg shows for the first time that people have at least two different kinds of brown fat cells - not just one as was previously thought. According to Sven Enerbäck, who heads the country's leading research group in the study of fat cells and metabolism, this is an interesting discovery.

"We already know that those of us who have more brown fat tissue have a smaller risk of developing type 2 diabetes. With these new results, we should eventually be able to develop methods for stimulating the brown fat tissue, so that some of the surplus energy we store in the form of fat tissue can be converted into heat. Such a treatment could both prevent obesity and reduce the risk of developing obesity-related diseases such as type 2 diabetes," says Sven Enerbäck.

The researchers call the new type of brown fat tissue that they have discovered "classical brown fat". According to the Gothenburg study, young people have this classic brown fat tissue, but it seems to disappear during adolescence.

"One idea is to be able to "reactivate" the classical brown fat tissue in older people and so treat obesity," says Sven Enerbäck.

The research into brown fat tissue is being done in close cooperation with researchers at Linköping University.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes